logo
Share SHARE
FONT-SIZE Plus   Neg

Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint

Eli Lilly and Co. (LLY) announced Monday that its MONARCH 2 breast cancer Study trial of abemaciclib met the primary endpoint of progression-free survival. Abemaciclib, in combination with fulvestrant, was superior to fulvestrant plus placebo in patients with HR+, HER2- advanced breast cancer, the company noted.

The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase or CDK 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive or HR+, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.

The results demonstrated the addition of abemaciclib to fulvestrant resulted in a statistically significant improvement in PFS, when compared to the control arm of placebo plus fulvestrant. Detailed efficacy and safety results will be presented at an upcoming medical meeting.

The global Phase 3, double-blind study was designed to evaluate the efficacy and safety of abemaciclib, in combination with fulvestrant, in patients with advanced breast cancer.

The most common adverse events observed were diarrhea, neutropenia, nausea and fatigue, and were consistent with the previous studies of abemaciclib.

Lilly intends to submit a new drug application or NDA for single-agent abemaciclib in the second quarter of 2017, based on the MONARCH 1 study.

Lilly plans to submit an additional application for MONARCH 2 in the third quarter of this year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
They say there's plenty of fish in the sea, but very few of them are as wealthy as these tycoons. May be they have been so busy building their empires they never had the time to stick with a perfect partner to build their family. This list of the richest singles is assorted — from a 34 year-old... Anthony Levandowski, the head of Uber's self-driving division, is stepping away from his role as Uber continues a legal battle with Waymo, Levandowski's former employer. Levandowski, who founded startup Otto, became head of Uber's Advanced Technologies Group or ATG after Otto was acquired by Uber in August 2016. Southwest Airlines Co. has decided to end the practice of overbooking flights, the airline's CEO Gary Kelly said Thursday. The airline's plan to end overbooking could be implemented from May 8, according to a Southwest spokeswoman.
comments powered by Disqus
Follow RTT